kynurenine has been researched along with Migraine Disorders in 17 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
Migraine Disorders: A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This review summarizes current knowledge of the role of kynurenine signalling in trigeminal and central pain processing, including its therapeutic prospects in migraine treatment." | 8.87 | The L-kynurenine signalling pathway in trigeminal pain processing: a potential therapeutic target in migraine? ( Ashina, M; Guo, S; Vecsei, L, 2011) |
| "Glutamate is a key player in migraine pathogenesis; it is crucial in the communication of first and second-order neurons, and it has an important role in the genesis of cortical spreading depression, which is the electrophysiological correlate for migraine aura and may be involved in the activation of the trigeminal system." | 6.48 | Kynurenines and headache. ( Bohár, Z; Fejes, A; Párdutz, A; Tar, L; Toldi, J; Vécsei, L, 2012) |
| " In recent years, migraine research focused on tryptophan, which is metabolized via two main pathways, the serotonin and kynurenine pathways, both of which produce neuroactive molecules that influence pain processing and stress response by disturbing neural and brain hypersensitivity and by interacting with molecules that control vascular and inflammatory actions." | 5.22 | Exploring the Tryptophan Metabolic Pathways in Migraine-Related Mechanisms. ( Körtési, T; Spekker, E; Vécsei, L, 2022) |
| "This review summarizes current knowledge of the role of kynurenine signalling in trigeminal and central pain processing, including its therapeutic prospects in migraine treatment." | 4.87 | The L-kynurenine signalling pathway in trigeminal pain processing: a potential therapeutic target in migraine? ( Ashina, M; Guo, S; Vecsei, L, 2011) |
| "The involvement of these pathways in migraine has been widely studied, but acute citalopram neuroendocrine challenge on TRP metabolism and cytokine profile has not been investigated yet." | 3.11 | Citalopram Neuroendocrine Challenge Shows Altered Tryptophan and Kynurenine Metabolism in Migraine. ( Bagdy, G; Dalmadi Kiss, B; Demeter, AK; Denes, A; Édes, AE; Gecse, K; Juhasz, G; Király, M; Környei, Z; Ludányi, K; Nagy, T; Virág, D, 2022) |
| "Changes in KP were reported in both migraine and FGIDs." | 2.72 | Kynurenine Pathway of Tryptophan Metabolism in Migraine and Functional Gastrointestinal Disorders. ( Blasiak, J; Chojnacki, C; Chojnacki, J; Fila, M; Pawlowska, E; Szczepanska, J, 2021) |
| "Migraine is a highly disabling neurovascular primary headache disorder, with its exact pathomechanism being still unrevealed." | 2.55 | Kynurenines and PACAP in Migraine: Medicinal Chemistry and Pathogenetic Aspects. ( Nagy-Grocz, G; Petrovics-Balog, A; Szok, D; Tajti, J; Toldi, J; Tuka, B; Vecsei, L, 2017) |
| "Migraine and neuropathic pain are common causes of chronic pain." | 2.52 | Drug targets of migraine and neuropathy: treatment of hyperexcitability. ( Balog, A; Majláth, Z; Tajti, J; Vécsei, L, 2015) |
| "Glutamate is a key player in migraine pathogenesis; it is crucial in the communication of first and second-order neurons, and it has an important role in the genesis of cortical spreading depression, which is the electrophysiological correlate for migraine aura and may be involved in the activation of the trigeminal system." | 2.48 | Kynurenines and headache. ( Bohár, Z; Fejes, A; Párdutz, A; Tar, L; Toldi, J; Vécsei, L, 2012) |
| "The treatment and prevention of migraine within the last decade has become largely pharmacological." | 1.43 | Migraine: A disorder of metabolism? ( Kokavec, A, 2016) |
| "These findings suggest that in migraine KYN is unidirectionally metabolized into ANA at expenses of KYNA and 3-HK." | 1.42 | Altered kynurenine pathway metabolites in serum of chronic migraine patients. ( Capi, M; Curto, M; Fazio, F; Giamberardino, MA; Lionetto, L; Martelletti, P; Negro, A; Nicoletti, F; Simmaco, M, 2015) |
| " Although kynurenic acid does not cross the BBB, its precursor, kynurenine, if combined with probenecid, crosses it readily." | 1.34 | Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model. ( Chadaide, Z; Fenyo, R; Knyihár-Csillik, E; Krisztin-Péva, B; Mihály, A; Németh, H; Toldi, J; Vécsei, L, 2007) |
| " The present investigation tested the hypothesis of whether kynurenine in combination with systemically administered probenecid protects second-order trigeminal neurons against stimulation arriving via central processes of trigeminal ganglion cells." | 1.34 | Prevention of electrical stimulation-induced increase of c-fos immunoreaction in the caudal trigeminal nucleus by kynurenine combined with probenecid. ( Chadaide, Z; Fenyo, R; Knyihár-Csillik, E; Krisztin-Péva, B; Németh, H; Toldi, J; Vécsei, L, 2007) |
| "We describe a patient whose migraine headaches responded dramatically to sustained-release niacin as preventive treatment." | 1.32 | Sustained-release niacin for prevention of migraine headache. ( Dodick, DW; Muir, JJ; Velling, DA, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Fila, M | 1 |
| Chojnacki, J | 1 |
| Pawlowska, E | 1 |
| Szczepanska, J | 1 |
| Chojnacki, C | 1 |
| Blasiak, J | 1 |
| Gecse, K | 1 |
| Édes, AE | 1 |
| Nagy, T | 1 |
| Demeter, AK | 1 |
| Virág, D | 1 |
| Király, M | 1 |
| Dalmadi Kiss, B | 1 |
| Ludányi, K | 1 |
| Környei, Z | 1 |
| Denes, A | 1 |
| Bagdy, G | 1 |
| Juhasz, G | 1 |
| Körtési, T | 2 |
| Spekker, E | 2 |
| Vécsei, L | 12 |
| Tóth, F | 1 |
| Fülöp, F | 2 |
| Szatmári, I | 1 |
| Toldi, J | 7 |
| Dékány, I | 1 |
| Nagy-Grócz, G | 2 |
| Zádor, F | 1 |
| Dvorácskó, S | 1 |
| Bohár, Z | 2 |
| Benyhe, S | 1 |
| Tömböly, C | 1 |
| Párdutz, Á | 3 |
| Curto, M | 2 |
| Lionetto, L | 2 |
| Fazio, F | 2 |
| Mitsikostas, DD | 1 |
| Martelletti, P | 2 |
| Majláth, Z | 1 |
| Balog, A | 1 |
| Tajti, J | 2 |
| Negro, A | 1 |
| Capi, M | 1 |
| Giamberardino, MA | 1 |
| Simmaco, M | 1 |
| Nicoletti, F | 1 |
| Kokavec, A | 1 |
| Szok, D | 1 |
| Tuka, B | 1 |
| Petrovics-Balog, A | 1 |
| Vamos, E | 1 |
| Klivenyi, P | 1 |
| Guo, S | 1 |
| Ashina, M | 1 |
| Fejes, A | 1 |
| Tar, L | 1 |
| Szalárdy, L | 1 |
| Velling, DA | 1 |
| Dodick, DW | 1 |
| Muir, JJ | 1 |
| Knyihár-Csillik, E | 2 |
| Mihály, A | 1 |
| Krisztin-Péva, B | 2 |
| Chadaide, Z | 2 |
| Németh, H | 2 |
| Fenyo, R | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Exploration of the Role of Tryptophan Metabolites in Pediatric Migraine[NCT05969990] | 200 participants (Anticipated) | Observational | 2022-01-01 | Recruiting | |||
| Effects of 3-month Probiotic Mix Supplementation (L. Helveticus R-0052, B. Longum R-0175) on Gut Microbiota and Metabolome, Endocannabinoid and Immune Systems Activation, Along With Symptoms of Fatigue in Professional Dancers[NCT05567653] | 60 participants (Anticipated) | Interventional | 2022-09-21 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for kynurenine and Migraine Disorders
| Article | Year |
|---|---|
Kynurenine Pathway of Tryptophan Metabolism in Migraine and Functional Gastrointestinal Disorders.
Topics: Animals; Brain; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Kynurenine; Migraine Disorders; | 2021 |
Exploring the Tryptophan Metabolic Pathways in Migraine-Related Mechanisms.
Topics: Humans; Kynurenic Acid; Kynurenine; Metabolic Networks and Pathways; Migraine Disorders; Pain; Serot | 2022 |
Exploring the Tryptophan Metabolic Pathways in Migraine-Related Mechanisms.
Topics: Humans; Kynurenic Acid; Kynurenine; Metabolic Networks and Pathways; Migraine Disorders; Pain; Serot | 2022 |
Exploring the Tryptophan Metabolic Pathways in Migraine-Related Mechanisms.
Topics: Humans; Kynurenic Acid; Kynurenine; Metabolic Networks and Pathways; Migraine Disorders; Pain; Serot | 2022 |
Exploring the Tryptophan Metabolic Pathways in Migraine-Related Mechanisms.
Topics: Humans; Kynurenic Acid; Kynurenine; Metabolic Networks and Pathways; Migraine Disorders; Pain; Serot | 2022 |
Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine.
Topics: Animals; Endocannabinoids; Humans; Kynurenine; Migraine Disorders; Receptors, Cannabinoid; Receptors | 2017 |
Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important.
Topics: Humans; Kynurenine; Metabolic Networks and Pathways; Migraine Disorders | 2015 |
Drug targets of migraine and neuropathy: treatment of hyperexcitability.
Topics: Animals; Excitatory Amino Acid Agents; Glutamic Acid; Humans; Hyperalgesia; Kynurenine; Migraine Dis | 2015 |
Kynurenines and PACAP in Migraine: Medicinal Chemistry and Pathogenetic Aspects.
Topics: Animals; Chemistry, Pharmaceutical; Glutamic Acid; Humans; Kynurenine; Migraine Disorders; Neurons; | 2017 |
The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection.
Topics: Alzheimer Disease; Animals; Brain; Brain Diseases; Brain Ischemia; Epilepsy; Humans; Huntington Dise | 2009 |
The L-kynurenine signalling pathway in trigeminal pain processing: a potential therapeutic target in migraine?
Topics: Animals; Humans; Kynurenine; Migraine Disorders; Pain; Pain Perception; Signal Transduction; Tryptop | 2011 |
Kynurenines and headache.
Topics: Animals; Brain Chemistry; Headache; Humans; Kynurenine; Migraine Disorders; Neural Pathways; Neuropr | 2012 |
Kynurenines in the CNS: recent advances and new questions.
Topics: Animals; Autoimmune Diseases; Central Nervous System Diseases; Drug Design; Drug Evaluation, Preclin | 2013 |
1 trial available for kynurenine and Migraine Disorders
| Article | Year |
|---|---|
Citalopram Neuroendocrine Challenge Shows Altered Tryptophan and Kynurenine Metabolism in Migraine.
Topics: Citalopram; Double-Blind Method; Female; Humans; Kynurenine; Migraine Disorders; Serotonin; Tryptoph | 2022 |
6 other studies available for kynurenine and Migraine Disorders
| Article | Year |
|---|---|
[Kynurenines and drug research].
Topics: Humans; Kynurenine; Migraine Disorders; Neurodegenerative Diseases | 2020 |
Altered kynurenine pathway metabolites in serum of chronic migraine patients.
Topics: Adult; Female; Humans; Hydroxyindoleacetic Acid; Kynurenic Acid; Kynurenine; Male; Middle Aged; Migr | 2015 |
Migraine: A disorder of metabolism?
Topics: Animals; Eating; Fasting; Female; Food; Glucose; Glucose Transporter Type 3; Glucose Transporter Typ | 2016 |
Sustained-release niacin for prevention of migraine headache.
Topics: Delayed-Action Preparations; Female; Humans; Kynurenine; Middle Aged; Migraine Disorders; Niacin; Se | 2003 |
Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Genes, fos; Immunohistochemistry; Kynure | 2007 |
Prevention of electrical stimulation-induced increase of c-fos immunoreaction in the caudal trigeminal nucleus by kynurenine combined with probenecid.
Topics: Adjuvants, Pharmaceutic; Afferent Pathways; Analgesics; Animals; Blood-Brain Barrier; Disease Models | 2007 |